Epidemiologic study of neural reserve and neurobiology of aging
Active Grant Awarded
- Award ID
- R56AG017917
- Recipient
-
Rush University Medical Center UEI C155UU2TXCP3
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,628,894
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 21% complete
- Place of performance
- Chicago, IL 60612, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Institute on Aging awarded Rush University Medical Center $2.628894 million on September 9, 2026, under Grant R56AG017917 in the Aging Research program (CFDA 93.866). The proposed renewal continues the Rush Memory and Aging Project (MAP), a prospective clinical-pathologic cohort study that began in 1997. The proposed work develops next-generation brain multi-omic molecular pseudotime and subtypes of resilience, defined as cognitive decline not explained by common brain pathologies. It validates these constructs in an independent sample of MAP brains, determines key drivers of pseudotime and subtypes, and clinically characterizes them in living participants. Investigators will continue following MAP participants, who consented to annual clinical evaluation and organ donation at death, with annual blood draws, DynaPort gait belt assessment, and biennial MRI.
Performance runs through August 31, 2027, with work performed in Chicago, Illinois 60612. The program funds biomedical and behavioral research on aging, with an emphasis on preventing and treating Alzheimer's disease and related dementias. The source identifies no sub-recipients for this award.
Description
- Abstract
- The prospective, analytic, clinical-pathologic cohort study, the rush memory and aging project (map), started in 1997. We find a dozen different ad/adrd brain pathologies in nearly 250 combinations across our autopsied participants. These brain pathologies collectively explain less than half the variance of cognitive decline and account for only 2/3RDS of ad dementia cases. Targeting each brain pathology and combination of pathologies for therapeutic interventions represents a daunting task and suggests alternate approaches are urgently needed. Next, we identified dozens of non-genomic risk factors for ad dementia, few of which correlated with any ad/adrd brain pathology, highlighting other pathways to ad/adrd dementia agnostic to brain pathologies, i.e., risk factors for "resilience" to ad/adrd pathologic traits. Our conceptual framework for resilience is grounded in its underlying neurobiology; we operationally define the construct as cognitive decline not explained by common brain pathologies. With this, we identified numerous genes, transcripts, epigenomic marks, proteins, glycoproteins, lipids, and metabolites associated with high or low resilience, many of which are potentially druggable, e.g., kinases. Together, these findings highlight the potential for therapies aimed at resilience to offset the effects of any combination of ad/adrd brain pathologies. The overall goal of the proposed renewal is to develop next generation brain multi-omic molecular pseudotime and subtypes of resilience, validate these constructs in an independent sample of map brains, determine key drivers of pseudotime and subtypes, and clinically characterize these constructs in living participants. We will continue to follow map participants, who consented to detailed annual clinical evaluation and organ donation at death including annual blood and dynaport gait belt, and biennial MRI, and generate brain dnam rnaseq, proteomics and metabolomics on map decedents to address the following aims: aim 1. Generate and validate a 4-omic brain molecular pseudotime of resilience to ad/adrd pathologies. Aim 2. Generate and validate 4-omic brain molecular subtypes of resilience to ad/adrd pathologies. Aim 3. Generate and validate key drivers of brain molecular pseudotime and subtypes of resilience to ad/adrd pathologies. Aim 4. Clinically characterize pseudotime and subtypes to translate brain omics to data from living persons. All aims are now supported with new and compelling preliminary data lending confidence that the project will be successful. All data and meta-data will be shared with the wider aging and dementia research community via the radc resource sharing hub and the adknowledge portal. Impact statement: the proposal lays the foundation for a new and potentially powerful path to precision medicine for resilience to ad/adrd pathologic traits, and creates an unprecedented, unique, and highly valued resource for the scientific community that will have a strong and sustained impact on the field.
Quick answers
Who received award R56AG017917?
R56AG017917 was awarded to Rush University Medical Center by National Institute on Aging (National Institutes of Health) on September 9, 2026.
How much is award R56AG017917 worth?
$2,628,894 has been obligated on R56AG017917.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award